Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study

• Váldodahkkit: M. Rossini (Dahkki), O. Viapiana (Dahkki), M. Vitiello (Dahkki), N. Malavolta (Dahkki), G. La Montagna (Dahkki), S. Maddali Bongi (Dahkki), O. Di Munno (Dahkki), R. Nuti (Dahkki), C.U. Manzini (Dahkki), C. Ferri (Dahkki), L. Bogliolo (Dahkki), A. Mathieu (Dahkki), F. Cantatore (Dahkki), A. Del Puente (Dahkki), M. Muratore (Dahkki), W. Grassi (Dahkki), B. Frediani (Dahkki), G. Saviola (Dahkki), P. Delvino (Dahkki), L. Mirone (Dahkki), G. Ferraccioli (Dahkki), G. Tripi (Dahkki), I. Piazza (Dahkki), D. Gatti (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: PAGEPress Publications, 2017-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Osteoporosis and fractures are common and invalidating consequences of chronic glucorticoid (GC) treatment. Reliable information regarding the epidemiology of GC induced osteoporosis (GIOP) comes exclusively from the placebo group of randomized clinical trials while observational studies are general...